OBJECTIVE: To investigate the relationship between bortezomib resistance and mutations in the proteasome beta5 subunit (PSMB5) gene. MATERIALS AND METHODS: Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection. Mutations were detected by sequencing the complementary DNA of the PSMB5 gene. Mutated clones were selected by limited dilution and cultured without bortezomib. Messenger RNA expression levels of PSMB5 in these mutated clones were measured by quantitative reverse transcription polymerase chain reaction. The degree of resistance was determined by cytotoxicity at various bortezomib concentrations. The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin. RESULTS: In addition to the previously reported PSMB5 G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones containing these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained. After being cultured without bortezomib for >2 months, no significant difference in PSMB5 messenger RNA levels was detected between these JurkatB cells and parental Jurkat cells. JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, respectively, to bortezomib compared to Jurkat cells. There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells. The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between. CONCLUSION: Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.
OBJECTIVE: To investigate the relationship between bortezomib resistance and mutations in the proteasome beta5 subunit (PSMB5) gene. MATERIALS AND METHODS: Various bortezomib-resistant lymphoblastic lymphoma/leukemia lines were established by repeated cycles of bortezomib selection. Mutations were detected by sequencing the complementary DNA of the PSMB5 gene. Mutated clones were selected by limited dilution and cultured without bortezomib. Messenger RNA expression levels of PSMB5 in these mutated clones were measured by quantitative reverse transcription polymerase chain reaction. The degree of resistance was determined by cytotoxicity at various bortezomib concentrations. The chymotrypsin-like activities were assayed by measuring the release of the fluorescent 7-amido-4-methylcoumarin from the substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin. RESULTS: In addition to the previously reported PSMB5G322A mutant (Ala49Thr), a C323T mutant (Ala49Val), and G322A, C326T conjoined mutant (Ala49Thr and Ala50Val) were selected and clones containing these mutations (JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T) were obtained. After being cultured without bortezomib for >2 months, no significant difference in PSMB5 messenger RNA levels was detected between these JurkatB cells and parental Jurkat cells. JurkatB-G322A, JurkatB-C323T, and JurkatB-G322A/C326T clones displayed 22.0-fold, 39.4-fold, and 66.7-fold resistance, respectively, to bortezomib compared to Jurkat cells. There were no significant differences between the chymotrypsin-like activities of these mutants and Jurkat cells. The inhibitory effect of bortezomib on chymotrypsin-like activity was the weakest in JurkatB-G322A/C326T cells, and the strongest in JurkatB-G322A cells, with JurkatB-C323T cells falling in between. CONCLUSION: Mutations of the PSMB5 gene resulting in substitutions of Ala49 and Ala50 of PSMB5 protein can confer varying bortezomib resistance.
Authors: Yuan Xiao Zhu; Rodger Tiedemann; Chang-Xin Shi; Holly Yin; Jessica E Schmidt; Laura A Bruins; Jonathan J Keats; Esteban Braggio; Chris Sereduk; Spyro Mousses; A Keith Stewart Journal: Blood Date: 2011-02-02 Impact factor: 22.113
Authors: Gaelen T Hess; Laure Frésard; Kyuho Han; Cameron H Lee; Amy Li; Karlene A Cimprich; Stephen B Montgomery; Michael C Bassik Journal: Nat Methods Date: 2016-10-31 Impact factor: 28.547
Authors: Deborah J Kuhn; Zuzana Berkova; Richard J Jones; Richard Woessner; Chad C Bjorklund; Wencai Ma; R Eric Davis; Pei Lin; Hua Wang; Timothy L Madden; Caimiao Wei; Veerabhadran Baladandayuthapani; Michael Wang; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Robert Z Orlowski Journal: Blood Date: 2012-08-29 Impact factor: 22.113
Authors: David I Lichter; Hadi Danaee; Michael D Pickard; Olga Tayber; Michael Sintchak; Hongliang Shi; Paul G Richardson; Jamie Cavenagh; Joan Bladé; Thierry Façon; Ruben Niesvizky; Melissa Alsina; William Dalton; Pieter Sonneveld; Sagar Lonial; Helgi van de Velde; Deborah Ricci; Dixie-Lee Esseltine; William L Trepicchio; George Mulligan; Kenneth C Anderson Journal: Blood Date: 2012-09-27 Impact factor: 22.113